A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer
Authors:
- Walburga Engel-RiedelWEWalburga Engel-Riedel
- Jamie LoweJLJamie Lowe
- Paulette MattsonPMPaulette Mattson
- J. Richard TroutJTJ. Richard Trout
- Richard D. HuhnRHRichard D. Huhn
- Michele GarganoMGMichele Gargano
- Myra L. PatchenMPMyra L. Patchen
- Richard WalshRWRichard Walsh
- My My TrinhMTMy My Trinh
- Mariève DupuisMDMariève Dupuis
- Folker SchnellerFSFolker Schneller
Open Access
- 27 February 2018
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 16
Abstract
Background BTH1677, a beta-glucan pathogen-associated molecular pattern molecule, drives an anti-cancer immune response in combination with oncology antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and safety of BTH1677 combined with bevacizumab/carboplatin/paclitaxel in patients with untreated advanced non-small cell lung cancer (NSCLC). Methods Patients were randomized to the BTH1677 arm (N = 61; intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W) or Control arm (N = 31; bevacizumab/carboplatin/paclitaxel as above). Carboplatin/paclitaxel was discontinued after 4-6 cycles and patients who responded or remained stable received maintenance therapy with BTH1677/bevacizumab (BTH1677 arm) or bevacizumab (Control arm). Efficacy assessments, based on blinded central radiology review, included objective response rate (ORR; primary endpoint), disease control rate, duration of objective response, and progression-free survival. Overall survival and adverse events (AEs) were also assessed. Results ORR was higher in the BTH1677 vs Control arm but the difference between groups was not statistically significant (60.4% vs 43.5%; P = .2096). All other clinical endpoints also favored the BTH1677 arm but none statistically differed between arms. PK was consistent with previous studies. Although a higher incidence of Grade 3/4 AEs occurred in the BTH1677 vs Control arm (93.2% vs 66.7%), no unexpected AEs were observed. Serious AEs and discontinuations due to AEs were lower in the BTH1677 vs Control arm. Conclusions Improvements in tumor assessments and survival were observed with BTH1677/bevacizumab/carboplatin/paclitaxel compared with control treatment in patients with advanced NSCLC. Trial registration ClinicalTrials.gov registration ID: NCT00874107. Registered 2 April 2009. First participant was enrolled on 29 September 2009.Keywords
This publication has 38 references indexed in Scilit:
- Harnessing the Immune System for the Treatment of Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-DependentFrontiers in Immunology, 2013
- Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient OutcomeJournal of Thoracic Oncology, 2011
- Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucansBlood, 2011
- Natural Innate and Adaptive Immunity to CancerAnnual Review of Immunology, 2011
- Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Annals of Oncology, 2010
- Effect of Yeast-derived β-glucan in Conjunction With Bevacizumab for the Treatment of Human Lung Adenocarcinoma in Subcutaneous and Orthotopic Xenograft ModelsJournal of Immunotherapy, 2009
- Yeast-Derived β-Glucan Augments the Therapeutic Efficacy Mediated by Anti–Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft ModelsClinical Cancer Research, 2008
- Combined Yeast β-Glucan and Antitumor Monoclonal Antibody Therapy Requires C5a-Mediated Neutrophil Chemotaxis via Regulation of Decay-Accelerating Factor CD55Cancer Research, 2007
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004